Severe hepatotoxicity due to osimertinib after nivolumab therapy in patients with non‐small cell lung cancer harboring EGFR mutation

BACKGROUND: Osimertinib is the most promising treatment option for patients with epidermal growth factor receptor (EGFR) mutation‐positive non‐small cell lung cancer (NSCLC) with acquired T790M resistance. However, recent studies have suggested that osimertinib could increase the frequency of seriou...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamaguchi, Ou, Kaira, Kyoichi, Kawasaki, Tomonori, Mouri, Atsuto, Hashimoto, Kosuke, Shiono, Ayako, Shinomiya, Shun, Miura, Yu, Nishihara, Fuyumi, Murayama, Yoshitake, Kobayashi, Kunihiko, Mochida, Satoshi, Kagamu, Hiroshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7113047/
https://www.ncbi.nlm.nih.gov/pubmed/32068351
http://dx.doi.org/10.1111/1759-7714.13363

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7113047/
https://www.ncbi.nlm.nih.gov/pubmed/32068351
http://dx.doi.org/10.1111/1759-7714.13363

Ejemplares similares